Login to Your Account



Ark Pushes Back Vitor To Collect Endpoint Data

By Nuala Moran


Wednesday, October 31, 2007
LONDON - Ark Therapeutics Group plc has backed off from moving Vitor, its treatment for cancer cachexia, into a full-scale Phase III trial after talks with the FDA. The company instead is opting to carry out a 60-patient pilot to gather further intelligence on endpoints and consider the design of the definitive 250 patient Phase III study. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription